

---

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please refer to the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

---

**\*Current Policy Effective Date: 1/1/26**

(See policy history boxes for previous effective dates)

### **Title: Positron Emission Tomography (PET) for Miscellaneous Applications (Non-Cardiac, Non-Oncologic)**

---

#### **Description**

##### **POSITRON EMISSION TOMOGRAPHY**

Positron emission tomography (PET) scans couple positron emitting radionuclide tracers to other molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit two high-energy photons in opposite directions that can be simultaneously detected (referred to as *coincidence detection*) by a PET scanner, which comprises multiple stationary detectors that encircle the region of interest.

---

#### **Medical Policy Statement**

Positron emission tomography (PET) scanning, including radiopharmaceutical agents: 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG, Florbetapir, Flutemetamol F18, **OR** Florbetaben F-18) has been established when criteria is met.

---

#### **Inclusionary and Exclusionary Guidelines**

##### **Inclusions:**

Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG), may be considered established when **ONE** of the following are met:

- The assessment of select patients with epileptic seizures who are candidates for surgery\*\*
- The diagnosis of chronic osteomyelitis
- One time evaluation to differentiate between frontotemporal dementia and Alzheimer's disease when substantial diagnostic uncertainty remains after **ALL** of the following have been completed

- Neuropsychological testing
- Evaluation by a physician who is experienced in neurodegenerative disease
- Structural imaging (CT or MRI)

Positron emission tomography (PET) of the brain of adults with cognitive impairment using **one** of the three radiopharmaceutical agents: Florbetapir, Flutemetamol F18, OR Florbetaben F-18 is established when all the criteria are met:

- Selection of individuals who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products

\*\*see policy guidelines below for clarification of surgery candidate

### **Exclusions:**

The use of FDG-PET using **any** of the three radiopharmaceutical agents: Florbetapir, Flutemetamol F18, **OR** Florbetaben F-18 is experimental/investigational for all other miscellaneous indications, **not listed in inclusion criteria** above including, but not limited to:

### **CNS diseases**

- Autoimmune disorders with CNS manifestations, including:
  - Behçet syndrome
  - Lupus erythematosus
- Cerebrovascular diseases, including:
  - Arterial occlusive disease (arteriosclerosis, atherosclerosis)
  - Carotid artery disease
  - Cerebral aneurysm
  - Cerebrovascular malformations (AVM and Moya-Moya disease)
  - Hemorrhage
  - Infarct
  - Ischemia
- Degenerative motor neuron diseases, including:
  - Amyotrophic lateral sclerosis
  - Friedreich ataxia
  - Olivopontocerebellar atrophy
  - Parkinson's disease
  - Progressive Supranuclear Palsy
  - Shy-Drager syndrome
  - Spinocerebellar Degeneration
  - Steele-Richardson-Olszewski disease
  - Tourette syndrome
- Dementias, including
  - Alzheimer disease
  - Multi-infarct dementia
  - Pick disease
  - Dementia with Lewy-Bodies
  - Presenile dementia
- Demyelinating diseases, such as multiple sclerosis
- Developmental, congenital, or inherited disorders, including:
  - Adrenoleukodystrophy
  - Down syndrome
  - Huntington chorea

- Kinky-hair disease (Menkes' syndrome)
- Sturge-Weber syndrome (encephalofacial angiomatosis) and the phakomatoses
- Miscellaneous
  - Chronic fatigue syndrome
  - Sick building syndrome
  - Post-traumatic stress disorder
- Nutritional or metabolic diseases and disorders, including:
  - Acanthocytosis
  - Hepatic encephalopathy
  - Hepatolenticular degeneration
  - Metachromatic leukodystrophy
  - Mitochondrial disease
  - Subacute necrotizing encephalomyelopathy
- Psychiatric diseases and disorders, including:
  - Affective disorders
  - Depression
  - Obsessive-compulsive disorder
  - Psychomotor disorders
  - Schizophrenia
- Pyogenic infections, including:
  - Aspergillosis
  - Encephalitis
- Substance abuse, including the CNS effects of alcohol, cocaine, and heroin
- Trauma, including brain injury and carbon monoxide poisoning
- Viral infections, including:
  - HIV/AIDS
  - AIDS dementia complex
  - Creutzfeldt-Jakob syndrome
  - Progressive multifocal leukoencephalopathy
  - Progressive rubella encephalopathy
  - Subacute sclerosing panencephalitis
- Mycobacterium infection
- Migraine
- Anorexia nervosa
- Assessment of cerebral blood flow in newborns
  - Vegetative versus "locked-in" state

### **Pulmonary diseases**

- Adult respiratory distress syndrome
- Diffuse panbronchiolitis
- Emphysema
- Obstructive lung disease
- Pneumonia

### **Musculoskeletal diseases**

- Spondylodiscitis
- Joint replacement follow-up

### **Other**

- Fever of unknown origin
- Giant cell arteritis

- Inflammation of unknown origin
- Inflammatory bowel disease
- Sarcoidosis
- Vascular prosthetic graft infection
- Vasculitis

## Policy Guidelines

In individuals with epileptic seizures, appropriate candidates are individuals with complex partial seizures who have failed to respond to medical therapy and have been advised to have a resection of a suspected epileptogenic focus located in a region of the brain accessible to surgery. Further, for the purposes of this review, conventional noninvasive techniques for seizure localization must have been tried with results suggesting a seizure focus but not sufficiently conclusive to permit surgery. The purpose of the positron emission tomography (PET) examination should be to avoid subjecting the individual to extended preoperative electroencephalographic recording with implanted electrodes or to help localize and minimize the number of sites for implanted electrodes to reduce the morbidity of that procedure.

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

### Established codes:

78608	78609	78811	78812	78813	78814
78815	78816	A9552	A9586	Q9982	Q9983

### Other codes (investigational, not medically necessary, etc.):

A9601	A9602
-------	-------

## Background

A variety of tracers are used for PET scanning, including oxygen 15, nitrogen 13, carbon 11, and fluorine 18. The radiotracer most commonly used in oncology imaging has been fluorine 18, coupled with fluorodeoxyglucose (FDG), which has a metabolism related to glucose metabolism. While FDG has traditionally been used in cancer imaging, it potentially has many other applications. There are other radiopharmaceutical agents such as Florbetapir, Flutemetamol F18, or Florbetaben F-18 which are used to determine the need for medication therapy for treatment of Alzheimer’s disease.

## Summary of Evidence

For individuals with epileptic seizures who are candidates for surgery who undergo fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET), the evidence includes systematic reviews (following the publication of 3 TEC Assessments). Relevant outcomes are symptoms, change in disease status, functional outcomes, health status measures, quality of

life (QOL), hospitalizations, medication use, and resource utilization. The TEC Assessment and Program in Evidence-based Care positron emission tomography (PET) recommendation report all concluded that FDG-PET accurately localizes the seizure focus compared with appropriate reference standards. A recent systematic review suggested it was difficult to discern the incremental value of FDG-PET in patients who have foci well localized by ictal scalp electroencephalography (EEG) and magnetic resonance imaging (MRI). The evidence on whether FDG-PET has a predictive value for a good surgical outcome is mixed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with suspected chronic osteomyelitis who receive FDG-PET, the evidence includes meta-analyses and a prospective study published after the meta-analyses. The relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, functional outcomes, quality of life, and hospitalizations. One systematic review and meta-analysis from 2013 of nine studies revealed that FDG-PET and FDG-PET plus computed tomography (CT) were useful for diagnosing suspected osteomyelitis in the foot of patients with diabetes. The results of the second meta-analysis showed that FDG-PET was the most accurate mode (pooled sensitivity, 96%; pooled specificity, 91%) for diagnosing chronic osteomyelitis. The results appear to be robust across fairly diverse clinical populations, which strengthen the conclusions. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected Alzheimer disease (AD) who receive FDG-PET to diagnose AD, the evidence includes systematic reviews of nonrandomized studies. Relevant outcomes are test validity, symptoms (cognitive and/or behavioral), change in disease status, functional outcomes, health status measures, and quality of life. The studies included in the reviews were generally of poor quality. There is no standard cutoff for FDG-PET positivity for diagnosing AD, and many studies have not included postmortem confirmation of AD as the reference standard, leading to uncertainty about estimates of performance characteristics. FDG-PET may have high sensitivity and specificity for diagnosing AD, but there is little evidence comparing the performance characteristics of clinical diagnosis using FDG-PET with the clinical diagnosis not using FDG-PET. Therefore, the incremental value of adding FDG-PET to the standard clinical diagnosis is unclear. No studies have reported on clinical outcomes of patients diagnosed with and without FDG-PET. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals to differentiate between frontotemporal lobe dementia and Alzheimer's disease when substantial diagnostic uncertainty and whose underlying pathological process is still unclear after a baseline imaging and evaluation by a dementia specialist. FDG-PET was given a Grade 1B recommendation by the National Institute on Aging for the differentiation of frontotemporal dementia from Alzheimer's disease. The technology may result in an improvement in the net health outcome of a specified group. The evidence is sufficient to determine that the technology results in an improvement in net health outcomes.

For individuals with suspected large vessel vasculitis (LVV) who receive FDG-PET, the evidence includes 7 systematic reviews of observational studies. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, morbid events, quality of life, hospitalizations, and treatment-related morbidity. Most studies included in the reviews were small and lacked controls. The reported performance characteristics were heterogeneous, but reviewers were unable to determine the source of heterogeneity. Studies

comparing PET to the true reference standard of biopsy or angiography were rare. There are no consensus criteria to define the presence of vascular inflammation by FDG-PET in large vessel vasculitis, and different parameters with visual and semiquantitative methods have been reported. Studies demonstrating changes in management based on PET results or improvements in clinical outcomes are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with diverse noncardiac or nononcologic conditions (e.g., central nervous system, pulmonary, and musculoskeletal diseases) who receive FDG-PET, the evidence includes a few systematic reviews. Relevant outcomes are overall survival, symptoms, change in disease status, functional outcomes, health status measures, quality of life, hospitalizations, medication use, and resource utilization. Many studies cited in the reviews were small, retrospective, and published in the 1990s to early 2000s; further, many studies did not directly compare 1 modality with another in the same patient group - nor did they correlate PET results in individual patients with improved clinical outcomes. Additional studies are needed to demonstrate that FDG-PET results can change management, and therefore improve patient outcomes to support the utility of FDG-PET. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

---

## **Rationale**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

### **Intractable Epilepsy**

#### **Clinical Context and Test Purpose**

The purpose of fluorine 18 fluorodeoxyglucose PET (FDG-PET) in individuals with epilepsy is to inform the decision on selecting treatment regimens.

The population of interest is patients with intractable epilepsy who are candidates for surgery.

Approximately one-third of patients with epilepsy do not achieve adequate seizure control with antiepileptic drugs.<sup>(8)</sup> Individuals with drug-resistant epilepsy are candidates for other treatments such as surgery. Many effective surgical procedures are available, and the treatment selected depends on characteristics of the seizures (e.g., the epileptogenic zone) and the extent to which it can be resected safely. Neuroimaging techniques, such as magnetic resonance imaging (MRI), electroencephalography (EEG), PET, single-photon emission computed tomography (CT), electric and magnetic source imaging, and magnetic resonance spectroscopy, have been used to locate the epileptic focus, thereby helping to guide the operative strategy. Some patients with epilepsy will have no identifiable MRI abnormality to help identify the focal region. PET, particularly using FDG, is a neuroimaging technique frequently used in patients being considered for surgery. FDG-PET produces an image of the

distribution of glucose uptake in the brain, presumably detecting focal areas of decreased metabolism.(9) PET may be able to correctly identify the focus in patients with unclear or unremarkable MRI results or discordant MRI and electroencephalographic results that could reduce the need for invasive electroencephalography. PET scanning may also help to predict which patients will have a favorable outcome following surgery. The Engel classification system often used to describe the surgical outcome, is as follows: class I: seizure-free (or free of disabling seizures); class II: nearly seizure-free; class III: worthwhile improvement; and class IV: no worthwhile improvement.(10)

### Systematic Reviews

A TEC Assessment (1996) reviewed the evidence on the use of PET in individuals with seizure disorders from 12 studies in which the results of PET scans were correlated with results of an appropriate reference standard test.(7) The highest quality blinded study (N=143) reported that PET correctly localized the seizure focus in 60% of patients, incorrectly localized it in 6%, and was inconclusive in 34%. Reviewers concluded that because localization can be improved with PET, selection of surgical candidates is improved and, therefore, PET for assessing patients who have medically refractory complex partial seizures and are potential candidates for surgery met TEC criteria. All other uses of PET for the management of seizure disorders did not meet the TEC criteria. Tables 1 and 2 summarize the characteristics and results of several meta-analyses of FDG-PET published since that TEC Assessment that have assessed either presurgical planning of patients who are candidates for epilepsy surgery or prediction of surgical outcomes. A brief discussion of each trial follows.

**Table 1. Characteristics of Systematic Reviews Assessing Use of FDG-PET for Epilepsy**

Study	Dates	Trials	N (Range)	Design	Duration
Courtney et al (2024)	1993-2022	98	4104	NR	12 to 60 months
Niu et al (2021)	1995-2020	44	2246 (6-194)	NR	NR
Jones et al (2016)	1946-2014	27	3163 (25-434)	OBS	≥ 1 year
Wang et al (2016)	2000-2015	18	391 (5-86)	NR	1-6.5 years
Burneo et al (2015)	1946-2013	39	2650	OBS	1 year, median
Englot et al (2012)	1990-2010	21 <sup>a</sup>	1199 (13-253) <sup>a</sup>	OBS	> 4 years
Willmann et al (2007)	1992-2006	46	1112 (2-117)	OBS	3 to 144 months

FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; OBS: observational; NR: not reported.

<sup>a</sup> Total number of studies and participants included; unclear if all studies included PET as a predictor.

Courtney et al (2024) conducted a meta-analysis of studies that described the association of localized hypometabolism seen on FDG-PET and outcome of epilepsy surgery.(76) Included studies had to report surgical outcome at least 12 months after surgery. The odds of achieving a favorable outcome (i.e., Engel class I, International League Against Epilepsy class 1 or 2, or seizure-free) after surgery (as determined by a random-effects analysis) was 2.68 (95% confidence interval [CI], 2.08 to 3.45) with localizing FDG-PET hypometabolism. Results were similar in patients with and without an epileptogenic lesion detected on MRI. Diffuse FDG-PET hypometabolism was associated with unfavorable outcomes (odds ratio [OR], 0.34; 95% CI, 0.22 to 0.54).

Niu et al (2021) conducted a meta-analysis of studies that described the concordance of FDG-PET with other methods (EEG and surgery) of identifying the epileptogenic zone in patients with epilepsy(11) A total of 44 studies (N=2246) of FDG-PET, FDG-PET/MRI, or <sup>11</sup>C-flumazenil-PET were identified. All but 3 studies used FDG-PET and the majority used <sup>18</sup>F-FDG-PET. Results are summarized in Table 2. Pooled sensitivity and specificity of FDG-PET were 0.66 (95% confidence interval [CI], 0.58 to 0.73) and 0.71 (95% CI, 0.63 to 0.78), respectively.

Jones et al (2016) published a systematic review of neuroimaging for surgical treatment of temporal lobe epilepsy.(12) Inclusion criteria were systematic reviews, randomized controlled trials (RCTs), or observational studies (with >20 patients and at least 1-year follow-up) of neuroimaging in the surgical evaluation for temporal lobe epilepsy. Reviewers searched EMBASE, PUBMED, and Cochrane from 1988 to 2014. Twenty-seven studies with 3163 patients were included in the review and 11 of these studies with 1358 patients (all observational designs) evaluated FDG-PET. Good surgical outcome was defined as Engel classes I and II. Meta-analysis was not performed. Results are summarized in Table 2.

Wang et al (2016) conducted a systematic review of prognostic factors for seizure outcomes in patients with MRI-negative temporal lobe epilepsy that included a search of PubMed.(13) Eighteen studies (N=391 patients) were included with a mean or median follow-up of more than 1 year. Seizure freedom was defined as freedom from any type of seizure or an Engel class I seizure outcome. Odds ratios and corresponding 95% confidence intervals (CIs) were calculated to compare the pooled proportions of seizure freedom between the groups who had localization of hypometabolism in the resected lobe versus those who did not. Table 2 shows the summary results.

Burneo et al (2015) published a recommendation report for the Program in Evidence-based Care and the PET steering committee of Cancer Care Ontario, which was based on a systematic review of studies of diagnostic accuracy and clinical utility of FDG-PET in the presurgical evaluation of adult and pediatric patients with medically intractable epilepsy.(14) The literature review included searches on PubMed, EMBASE, and OVID, and Cochrane databases. Systematic reviews, RCTs, and observational studies that evaluated the use of FDG-PET in medically intractable epilepsy were eligible for inclusion. Reviewers included 39 observational studies (N=2650 participants) in the qualitative review. Good surgical outcome was defined as Engel class I, II, or III, seizure-free, or significant improvement (<10 seizures per year and at least a 90% reduction in seizures from the preoperative year). Due to heterogeneity in patient populations, study designs, outcome measurements, and methods of PET interpretation, pooled estimates were not provided but ranges are shown in Table 2.

Englot et al (2012) performed a systematic review of predictors of long-term seizure freedom after surgery for frontal lobe epilepsy; they included articles found through a PUBMED search that had at least 10 participants and 48 months of follow-up.(15) Long-term seizure freedom was defined as Engel class I outcome. Twenty-one studies (N=1199 patients) were included; the number of studies that specifically addressed PET was not specified. Results are summarized in Table 2. The reviewers found that PET scans did not predict seizure freedom.

Willmann et al (2007) conducted a meta-analysis on the use of FDG-PET for preoperative evaluation of adults with temporal lobe epilepsy, which included 46 studies identified through a PubMed search.(16) Follow-up ranged from 3 to 144 months. Engel class I and II were defined as a good surgical outcome. The prognostic positive predictive value for ipsilateral PET hypometabolism was calculated but the reviewers noted significant variation in study designs and lack of precise data. Reviewers found that ipsilateral PET hypometabolism had a predictive value for a good outcome of 86% (see Table 2). The incremental value of PET was unclear.

**Table 2. Results of Systematic Reviews on Use of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography for Epilepsy**

Study	Studies	N	Outcomes	Estimate or Range	95% CI	<i>I</i> <sup>2</sup>	p
-------	---------	---	----------	-------------------	--------	-----------------------	---

Courtney et al (2024)	98	4108	Surgical outcome	OR of favorable outcome when localizing FDG-PET hypometabolism was identified, 2.68	2.08 to 3.45	30.89 %	NR
Niu et al (2021)	44	2246	Concordance with reference standard (EEG or surgical outcome)	Pooled concordance (overall), 0.67	0.60 to 0.73	90.5%	0.00
Jones et al (2016)	11	1358	Surgical outcome	<ul style="list-style-type: none"> <li>No overall summary given</li> <li>Reported conflicting findings on prognostic importance of PET-identified focal hypometabolism</li> </ul>	No pooling		
Wang et al (2016)	5	NR	Surgical outcome (freedom from seizures)	OR for PET hypometabolism positive vs negative, 2.11	0.95 to 4.65	0	0.06
Burneo et al (2015)	8	310	Percent agreement, localization with PET vs EEG	<ul style="list-style-type: none"> <li>56%-90% overall (adults)</li> <li>63%-90% in temporal lobe epilepsy (adults)</li> </ul>	No pooling		
	13	1064	Prognostic accuracy (good surgical outcome)	36%-89% (adults)	No pooling		
	6	690	Clinical decisions (influence decision making)	<ul style="list-style-type: none"> <li>53%-71% (adults)</li> <li>51%-95% (children)</li> </ul>	No pooling		
Englot et al (2012)	21 <sup>a</sup>	1199 <sup>a</sup>	Prognostic accuracy (good surgical outcome)	% for PET focal vs PET nonfocal, 52% vs 48%	NR	NR	0.61
Willmann et al (2007)	46	1112	Prognostic accuracy (good surgical outcome)	PPV=86%	NR	NR	NR

CI: confidence interval; EEG: electroencephalography; NR: not reported; OR: odds ratio; PET: positron emission tomography; PPV: positive predictive value.

<sup>a</sup> Total number of studies and participants included; unclear if all studies included PET as a predictor.

### Observational Studies

Traub-Weidinger et al (2016) reviewed a database of pediatric patients with epilepsy who underwent hemispherotomy and were evaluated with both FDG-PET and MRI before surgery (n=35).<sup>(17)</sup> Identifying the hemisphere harboring the epileptogenic zone before surgery has been shown to improve surgical outcomes. Seizure outcomes were measured using International League Against Epilepsy classifications. At 12 months post-surgery, 100% of patients with unilateral FDG-PET hypometabolism were seizure-free, while 95% of patients with unilateral lesions identified by MRI were seizure-free. For patients with bilateral FDG-PET hypometabolism, 75% were seizure-free at 12 months, while 71% of patients with bilateral lesions identified by MRI were seizure-free.

The recommendation report by Burneo et al (2015) discussed 3 retrospective studies demonstrating the impact of FDG-PET on clinical management of adults with epilepsy and three retrospective studies on change in clinical management based on FDG-PET results in children with epilepsy.<sup>(14)</sup> After receiving FDG-PET results on adults, some clinicians changed surgical decisions, used the results to guide intracranial EEGs, and ruled out an additional evaluation of the patient. Among pediatric patients who underwent FDG-PET, clinicians reported using the results to alter surgical decisions, classify symptomatic infantile spasms,

and avoid invasive monitoring due to localizing information. The study results were not pooled due to heterogeneity among the study designs and patient populations.

Removed the section summary for intractable seizures as information was previously captured in the above summary of evidence.

## **Suspected Chronic Osteomyelitis**

### **Clinical Context and Test Purpose**

The purpose of FDG-PET in individuals with chronic osteomyelitis is to confirm a diagnosis or to inform the decision on selecting treatment regimens.

Diabetic foot infections cause substantial morbidity and are a frequent cause of lower-extremity amputations. Foot infections can spread to contiguous deep tissues including the bone. Diagnosis of osteomyelitis is challenging. The reference standard for diagnosis is an examination of bacteria from a bone biopsy along with histologic findings of inflammation and osteonecrosis. In an open wound, another potential test for osteomyelitis is a probe-to-bone test, which involves exploring the wound for palpable bone using a sterile blunt metal probe.(18) Plain radiographs are often used as screening tests before biopsy, but they tend to have low specificity especially in early infection. When radiographs are inconclusive, a more sophisticated imaging technique can be used. Neither MRI nor computed tomography (CT), both of which have high sensitivity in diagnosing osteomyelitis, can be used in patients with metal hardware.(19) FDG-PET has high resolution that should be an advantage for accurate localization of leukocyte accumulation and can be used when MRI is not possible or inconclusive; in addition, PET semiquantitative analysis could facilitate the differentiation of osteomyelitis from noninfectious conditions such as neuropathic arthropathy.

### **Systematic Reviews**

Jin et al (2024) conducted a systematic review and meta-analysis of 9 studies that compared FDG-PET and MRI or white blood cell scintigraphy in diagnostic efficacy for foot osteomyelitis in patients with diabetes.(87) The overall sensitivity and specificity of FDG-PET was 0.83 (95% CI, 0.69 to 0.94) and 0.92 (95% CI, 0.86 to 0.97), respectively. There was no statistical difference in sensitivity and specificity between FDG-PET and MRI or white blood cell scintigraphy (all  $p > .05$ ).

Llewellyn et al (2020) conducted a systematic review and meta-analysis of 36 studies that reported the accuracy of imaging modalities for diagnosing osteomyelitis in patients with diabetic foot ulcer.(20) Various imaging techniques were included: PET, MRI, CT, x-rays, planar scintigraphy, ultrasound, and single-positron emission CT. Analysis of the 6 studies that used PET showed high specificity (92.8%; 95% CI, 75.7% to 98.2%;  $I^2 = 0\%$ ) and moderate sensitivity (84.3%; 95% CI, 52.8% to 96.3%;  $I^2 = 0\%$ ). The overall positive rate for PET was 45.9% (95% CI, 27.81% to 75.69%;  $I^2 = 36\%$ , which was lower than other modalities including MRI and scintigraphy. PET had a PPV of 88.6% and negative predictive value (NPV) of 85.4%. The authors concluded that PET had similar diagnostic accuracy to MRI for diagnosing osteomyelitis.

Lauri et al (2017) published a systematic review of 27 trials of diabetic patients with suspicion of osteomyelitis of the foot that compared the diagnostic performance of several imaging techniques.(21) MRI, technetium 99m hexamethylpropyleneamineoxime white blood cell (WBC) scan, indium In 111 oxyquinoline WBC scan, or FDG-PET plus CT were assessed. In

this population, the sensitivity and specificity of FDG-PET/CT (6 studies; 254 patients) were 89% (95% CI, 68% to 97%) and 92% (95% CI, 85% to 96%), respectively. The diagnostic odds ratio for FDG-PET was 95, and the positive and negative likelihood ratios were 11 and 0.11, respectively. Of the 4 modalities included, FDG-PET/CT and technetium 99m hexamethylpropyleneamineoxime WBC scans had greater specificity (both 92%) than MRI or indium In 111 oxyquinoline WBC scans (both 75%). Sensitivity did not differ significantly between modalities: 93% for MRI, 92% for indium In 111 oxyquinoline WBC, 91% for technetium 99m hexamethylpropyleneamineoxime WBC, and 89% for FDG-PET. The review was limited by the small size of studies included, which precluded subgroup or meta-regression analyses.

A systematic review by Treglis et al (2013) assessed 9 studies (n=299 patients), FDG-PET and PET with CT were found to be useful for assessing suspected osteomyelitis in the foot of patients with diabetes.(22) A meta-analysis of four studies found sensitivity of 74% (95% confidence interval [CI], 60% to 85%), specificity of 91% (95% CI, 85% to 96%), positive likelihood ratio of 5.56 (95% CI, 2.02 to 15.27), negative likelihood ratio of 0.37 (95% CI, 0.10 to 1.35), and diagnostic odds ratio of 16.96 (95% CI, 2.06 to 139.66).The summary area under the receiver operating characteristic curve (AUROC) was 0.874.

Termaat et al (2005) conducted a systematic review and of diagnostic imaging to assess chronic osteomyelitis.(21) Reviewers assessed 6 imaging approaches to chronic osteomyelitis, including FDG-PET and concluded that PET was the most accurate mode (pooled sensitivity, 96%; 95% CI, 88% to 99%; pooled specificity, 91%; 95% CI, 81% to 95%) for diagnosing chronic osteomyelitis. Leukocyte scintigraphy was adequate in the peripheral skeleton (sensitivity, 84%; 95% CI, 72% to 91%; specificity, 80%; 95% CI, 61% to 91%) but was inferior in the axial skeleton (sensitivity, 21%; 95% CI, 11% to 38%; specificity, 60%; 95% CI, 39% to 78%). The assessment of PET was based on 4 prospective European studies published between 1998 and 2003, (N=1660 patients). However, the study populations varied and included the following: (1) 57 patients with suspected spinal infection referred for FDG-PET and who had previous spinal surgery but not “recently” (24); (2) 22 trauma patients scheduled for surgery who had suspected metallic implant-associated infection (23); (3) 51 patients with recurrent osteomyelitis or osteomyelitis symptoms for more than 6 weeks, 36 in the peripheral skeleton and 15 in the central skeleton (24); and (4) 30 consecutive nondiabetic patients referred for possible chronic osteomyelitis.(27) The results appeared to be robust across fairly diverse clinical populations, which strengthen the conclusions.

### ***Prospective Studies***

Rastogi et al (2016) published a study comparing the efficacy of FDG-PET plus CT with contrast-enhanced MRI in the detection of diabetic foot osteomyelitis in patients with Charcot neuroarthropathy.(28) Patients with suspected diabetic foot osteomyelitis (N=23) underwent radiographs, FDG-PET/CT, and contrast-enhanced MRI. Bone culture, which is considered the criterion standard, identified 12 of the 23 patients with osteomyelitis. The sensitivity, specificity, PPV, and NPV of FDG-PET/CT in diagnosing osteomyelitis were 83%, 100%, 100%, and 85%, respectively. The same measures for contrast-enhanced MRI were 83%, 64%, 71%, and 78%, respectively.

Diagnosing osteomyelitis is challenging and FDG-PET may provide additional information along the diagnostic pathway. Currently, bone biopsy is considered the reference standard, and radiographs are often used as screening tests prior to bone biopsy. When radiographs are inconclusive, other imaging techniques have been used, such as MRI and CT. While MRI has

been shown to have a high sensitivity in diagnosing osteomyelitis, FDG-PET has also been shown to have high sensitivity and can be used when MRI is inconclusive or not possible (e.g., patients with metal hardware).

## Fluorine 18 Fluorodeoxyglucose (FDG) Positron Emission Tomography to Confirm a Diagnosis of Alzheimer Disease

### Clinical Context and Test Purpose

The purpose of fluorine 18 fluorodeoxyglucose PET (FDG-PET) in individuals with suspected AD is to confirm a diagnosis of AD. Fluorine 18 fluorodeoxyglucose PET (FDG-PET) quantifies brain function by measuring glucose levels. FDG-PET is proposed as a method to distinguish AD from other dementias through identifying distinct regions of hypometabolism.

A definitive diagnosis of AD requires histopathologic examination of brain tissue obtained by biopsy or autopsy. In practice, clinical criteria based on clinical examination, neurologic and neuropsychological examinations, and interviews with informants (e.g., family members or caregivers) are used to diagnose AD by excluding other diseases that can cause similar symptoms and distinguish AD from other forms of dementia.

### Systematic Reviews

Summaries of characteristics and results of several meta-analyses of early diagnosis of Alzheimer disease (AD) in people with cognitive impairment or for differentiating between potential causes of dementia are shown in Tables 3 and 4 and are briefly described below.

**Table 3. Characteristics of Systematic Reviews on Use Assessing FDG-PET for AD and Dementia**

Study	Dates	Studies	N (Range)	Design	Outcomes
Zhu et al (2022)	Up to 2020	16	NR	OBS	Diagnostic accuracy for predicting conversion from MCI to AD
Smailagic et al (2015)	1999-2013	16	697 (19-94)	OBS	Diagnostic accuracy for predicting conversion from MCI to AD
Davison et al (2014)	Up to 2013	8	197 (7-199)	OBS	Diagnostic accuracy for diagnosis of AD, differential diagnosis in dementia, predicting conversion from MCI to AD
Bloudek et al (2011)	1990-2010	119	NR	OBS	Diagnostic accuracy for diagnosis of AD, differential diagnosis in dementia
Yuan et al (2009)	2001-2005	6	280 (17-128)	OBS	Diagnostic accuracy for predicting conversion from MCI to AD
Matchar et al (2001)	1995-2001	18	1018 (10-138)	OBS	Diagnostic accuracy for distinguishing AD from healthy controls and for differential diagnosis in dementia

AD: Alzheimer disease; FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; MCI: mild cognitive impairment; NR: not reported; OBS: observational.

Zhu et al (2022) conducted a meta-analysis of cerebral perfusion imaging methods (FDG-PET, SPECT, and MRI) in the assessment of MCI conversion to AD. A total of 16 studies were included (5 with FDG-PET).<sup>(86)</sup> The authors found significantly higher sensitivity, specificity, and positive likelihood ratio with FDG-PET than SPECT or MRI. The studies for FDG-PET were determined to have low risk of bias.

Sailagic et al (2015) conducted a Cochrane review to assess the diagnostic accuracy of FDG PET for detecting people who clinically convert to Alzheimer disease dementia or other forms

of dementia at follow-up.(81) Included studies evaluated the diagnostic accuracy of FDG-PET to determine the conversion from MCI to AD or to other forms of dementia. Sixteen studies (total n=697 participants) were included in the qualitative review and 14 studies (n=421 participants) were included in the analysis. Because there are no accepted thresholds to define positive findings based on PET scans and studies used mixed thresholds for diagnosis, reviewers used a hierarchical summary receiver operating characteristic curve to derive pooled estimates of performance characteristics at fixed values. Five studies evaluated the accuracy of FDG-PET for all types of dementia. The sensitivities ranged between 46% and 95% while the specificities were between 29% and 100%; however, a meta-analysis could not be conducted because of the small number of studies sample sizes. Reviewers indicated that most studies were poorly reported and had an unclear risk of bias, mainly for the reference standard and participant selection domains.

In a systematic review (quality assessment of included studies was not reported), Davison et al (2014) reported on studies on the diagnostic performance of FDG-PET and single-photon emission computed tomography (SPECT) identified through a PUBMED search.(82) Three studies (197 patients) used histopathology as the reference standard. In patients with or without a clinical diagnosis of AD, sensitivity was 84% and specificity was 74%; in patients with memory loss or dementia, sensitivity was 94% and specificity was approximately 70%; in patients undergoing evaluation for dementia, sensitivity was 94% and specificity was 73%. Precision estimates were not given. In three different studies (271 participants), the sensitivities and specificities of FDG-PET for distinguishing AD from Lewy body dementia ranged from 83% to 99% and from 71% to 93%, respectively. And in two studies (183 participants), for predicting conversion from MCI to AD, sensitivity and specificity of PET were 82% and 57% versus 78% and 67%, respectively.

Bloudek et al (2011) assessed diagnostic strategies for AD in a meta-analysis.(83) Reviewers included 119 studies of diagnostic performance characteristics published from 1990 to 2010. Studies were identified through a search of PUBMED and included imaging, biomarkers, and clinical diagnostic strategies. Twenty studies included performance characteristics of FDG-PET for diagnosing AD compared to normal, nondemented controls. Thirteen studies described characteristics of FDG-PET for diagnosing AD compared to demented controls. FDG-PET demonstrated the highest area under the ROC curve, sensitivity, and specificity among all of the diagnostic methods for distinguishing AD from normal controls but had almost the lowest ROC comparing AD to non-AD demented controls (excluding MCI) due primarily to the low specificity in this group.

In a meta-analysis, Yuan et al (2009) compared the prognostic capacity of FDG-PET, SPECT, and structural MRI to predict patients' conversion from MCI to AD.(84) Using 24 articles (total n=1112 patients) published between 1990 to 2008 (6 studies with 280 patients on FDG-PET, published 2001-2005), reviewers found no statistically significant difference among the 3 modalities in pooled sensitivity, pooled specificity, or negative likelihood ratio. There was strong evidence of between-study heterogeneity and marked asymmetry in the funnel plot (with studies missing from the bottom left quadrant), indicating possible publication bias of studies with null results. Efforts to identify sources of heterogeneity (e.g., publication year, age, male-female ratio, follow-up interval, years of education, mean Mini-Mental State Examination score at baseline) yielded no significant results.

Using decision-analysis modeling, Matchar et al (2001) performed a technology assessment for the Agency for Healthcare Research and Quality to examine whether the use of FDG-PET

would improve health outcomes for diagnosis of AD in three clinical populations: patients with dementia, patients with MCI, and subjects with no symptoms but with a first-degree relative with AD.(85) For the review, a search was performed using PUBMED, CINAHL, and the HealthSTAR databases. Eighteen articles (total n=1018 participants) were included. The reference standard used in the studies was either histopathology or clinical diagnosis. Studies reported on various cutoffs for PET positivity, and therefore, an unweighted summary receiver operating characteristic method was used to calculate the pooled area under the curve. Reviewers concluded that outcomes for all 3 groups were better if all patients were treated with agents such as cholinesterase inhibitors rather than limiting treatment to patients based on FDG-PET results. The rationale was that the complications of treatment were relatively mild, and treatment was considered to have some degree of efficacy in delaying the progression of AD.

**Table 4. Results of Systematic Review on Use Assessing FDG-PET for AD and Dementia**

Study	Studies	N	Outcomes	Estimate (95% CI)
Zhu et al (2022)	5a	NR	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity: 87.2% (81.3% to 92.1%)</li> <li>• Specificity: 89.35% (77.6% to 91.8%)</li> <li>• PLR: 5.973 (3.15 to 6.72)</li> <li>• NLR: 0.132 (0.05 to 0.49)</li> </ul>
Smailagic et al (2015)	14	421	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity range: 25%-100%</li> <li>• Specificity range: 15%-100%</li> <li>• PLR: 4.03 (2.97 to 5.47)</li> <li>• NLR: 0.34 (0.15 to 0.75)</li> </ul>
Davison et al (2014)	3	197	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity: 84%</li> <li>• Specificity: 74%</li> </ul>
	2	183	Diagnostic accuracy, predicting conversion from MCI to AD	<ul style="list-style-type: none"> <li>• Sensitivity range: 57%-82%</li> <li>• Specificity range: 67%-78%</li> </ul>
	5	292	Diagnostic accuracy, differentiating AD and LBD	<ul style="list-style-type: none"> <li>• Sensitivity range: 83%-92%</li> <li>• Specificity range: 67%-93%</li> </ul>
Bloudek et al (2011)	20	NR	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity: 90% (84% to 94%)</li> <li>• Specificity: 89% (81% to 94%)</li> </ul>
	13	NR	Diagnostic accuracy, AD vs other dementia	<ul style="list-style-type: none"> <li>• Sensitivity: 92% (84% to 96%)</li> <li>• Specificity: 78% (69% to 85%)</li> </ul>
Yuan et al (2009)	6	280	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity: 89% (92% to 94%)</li> <li>• Specificity: 85% (78% to 90%)</li> <li>• PLR: 4.6 (3.2 to 6.7)</li> <li>• NLR: 0.15 (0.05 to 0.48)</li> </ul>
Matchar et al (2001)	15	729	Diagnostic accuracy	<ul style="list-style-type: none"> <li>• Sensitivity: 88% (79% to 94%)</li> <li>• Specificity: 87% (77% to 93%)</li> </ul>
	3	289	Diagnostic accuracy, distinguishing AD from non-AD dementia	<ul style="list-style-type: none"> <li>• Sensitivity range: 86% to 95%</li> <li>• Specificity range: 61% to 74%</li> </ul>

AD: Alzheimer disease; CI: confidence interval; FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; LBD: Lewy body dementia; MCI: mild cognitive impairment; NLR: negative likelihood ratio; NR: not reported; PLR: positive likelihood ratio.

a Includes only the 5 studies with FDG-PET.

There is no direct evidence of the clinical utility of FDG-PET for diagnosing AD.

The American College of Radiology indicates that advanced imaging modalities (i.e., FDG-PET) are not routinely used in community or general practices for the diagnosis or differentiation of forms of dementia.(92) However, FDG-PET may be useful in select

circumstances as a problem-solving technique to direct management. The European Federation of Neurological Societies recommends its use in those cases where the diagnosis remains in doubt after clinical and structural MRI workup and in particular clinical settings.(94) Gauthier et al (2012) discussed the recommendations made by the National Institute on Aging – Alzheimer Association workgroups at the 4th Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia. An 18F-FDG PET was determined to be useful in forming a differential diagnosis for a patient with a diagnosis of dementia who has undergone the recommended baseline clinical and structural brain imaging evaluation and who has been evaluated by a dementia specialist but whose underlying pathological process is still unclear, preventing adequate clinical management (Grade 1B).(95)

## Suspected Large Vessel Vasculitis

### Clinical Context and Test Purpose

The purpose of FDG-PET in individuals with suspected large vessel vasculitis (LVV) is to confirm a diagnosis or to inform the decision on selecting treatment regimens.

LVV causes granulomatous inflammation primarily of the aorta and its major branches.(29) There are two major types of LVV: giant cell arteritis (GCA) and Takayasu arteritis (TA). Classification criteria for GCA and TA were developed by American College of Rheumatology (ACR) in 1990.(30,31) The definitions have since been refined by the International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (2012).(32) Biopsy and angiography are considered the criterion standard techniques for diagnosis, but they are invasive and detect changes that occur late in the disease. In practice, the diagnosis is challenging because patients tend to have nonspecific symptoms such as fatigue, loss of appetite, weight loss, and low-grade fever as well as nonspecific lab findings such as increased C-reactive protein or erythrocyte sedimentation rate.(33) Misdiagnosis is common particularly during the early stages of the disease. Unfortunately, late diagnosis can lead to serious aortic complications and death. Since activated inflammatory cells accumulate glucose, FDG-PET may be able to detect and visualize early inflammation in vessel walls and facilitate early diagnosis thereby allowing treatment with glucocorticoids before irreversible arterial damage has occurred.

Summaries of characteristics and results of several meta-analyses of FDG-PET that have been published on the diagnosis and management of large vessel vasculitis (LVV) are shown in Tables 5 and 6 and are briefly described below.

**Table 5. Characteristics of Systematic Reviews on Use of FDG-PET for Large Vessel Vasculitis**

Study	Dates	Studies	N (Range)	Design	Outcomes
Gonzalez-Garcia et al (2024)	2018-2022	17	1042 (19 to 84)	OBS	Prevalence of extracranial LVV
Van der Geest et al (2021)	1987-2020	21	798 (11-112)	OBS	Diagnostic accuracy for relapsing/refractory disease
Lee et al (2016)	Up to 2015	8	400 (21-93)	OBS	Diagnostic accuracy for GCA and TA
Soussan et al (2015)	2000-2013	21	712 (18-93)	OBS	Diagnostic accuracy for GCA; assessment of disease activity in TA
Puppo et al (2014)	1999-2014	19	977 (8-304)	OBS	Diagnostic accuracy for GCA
Treglia et al (2011)	Up to 2011	32	604	OBS	Diagnostic accuracy for GCA and TA; assessment of disease activity; monitor treatment response
Besson et al (2011)	Up to 2011	14	Unclear	OBS	Diagnostic accuracy for GCA

FDG-PET: fluorine 18 fluorodeoxyglucose positron emission tomography; GCA: giant cell arteritis; OBS: observational; TA: Takayasu arteritis.

A meta-analysis by Gonzalez-Garcia et al (2024) evaluated the prevalence of extracranial LVV using FDG-PET/CT in patients with GCA and polymyalgia rheumatica.(96) Seventeen studies were included in the analysis. The prevalence of extracranial LVV in patients with GCA was 60.1%, and in patients with polymyalgia rheumatica was 41.8% ( $p=.006$ ). The analysis is limited by high heterogeneity, a small number of patients in each study and the use of various clinical criteria among studies as the reference standard.

A meta-analysis by van der Geest et al (2021) evaluated the diagnostic accuracy of FDG-PET/CT for monitoring LVV treatment response.(34)The investigators identified 21 studies for systematic review and 8 studies for meta-analysis. Most studies used ACR criteria as the reference standard. An analysis of 4 studies (N=111 patients with 136 scans) showed that FDG-PET/CT had a sensitivity and specificity of 77% and 71%, respectively for distinguishing between active disease and clinical remission. A summary of the results is presented in Table 4.

Lee et al (2016) performed a meta-analysis of the diagnostic accuracy of FDG PET or PET/CT for LVV.(35) The research included studies indexed in PubMed, EMBASE, or Cochrane Library that used the ACR classification system as the reference standard diagnosis. Eight studies were (N=400 participants) were identified for inclusion. Five studies included participants with both giant cell arteritis (GCA) and Takayasu arteritis (TA) while 3 included only GCA. Five studies evaluated FDG-PET and 3 evaluated FDG-PET/CT. Pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were calculated using a random-effects model and are shown in Table 6. Interpretation of these results is limited by the use of ACR as the reference standard and the varying levels of disease activity in selected studies.

Soussan et al (2015) conducted a literature review assessing the role of FDG-PET in the management of LVV, focused on 3 issues: determining the FDG-PET criteria for diagnosing vascular inflammation; establishing the performance of FDG-PET for the diagnosis of large-vessel inflammation in GCA patients; and defining the performance of FDG-PET to evaluate the disease inflammatory activity in patients with TA.(36) The PUBMED, Cochrane Library, and EMBASE databases were searched for articles that evaluated the value of FDG-PET in LVV. Selection criteria included the use of the ACR classification for GCA or TA, the definition of a positive amyloid threshold for PET, and more than four cases included. The sensitivity and specificity of FDG-PET for the diagnosis of large-vessel inflammation were calculated from each selected study and then pooled for meta-analysis with a random-effects model. Disease activity was assessed with the National Institutes of Health Stroke Scale (40) or another activity assessment scale. Twenty-one studies (413 patients, 299 controls) were included in the systematic review. FDG-PET showed FDG vascular uptake in 70% (288/413) of patients and 7% (22/299) of controls. Only vascular uptake equal to or higher than the liver uptake differed significantly between GCA plus TA patients and controls ( $p<0.001$ ). A summary of the results is shown in Table 6. FDG-PET showed good performances in the diagnosis of large-vessel inflammation, with higher accuracy for diagnosing GCA patients than for detecting activity in TA patients. Although a vascular uptake equal to or higher than the liver uptake appears to be a good criterion for the diagnosis of vascular inflammation, further studies are needed to define the threshold of significance as well as the clinical significance of the vascular uptake.

A systematic review by Puppo et al (2014) included studies of FDG-PET in GCA comparing the diagnostic performance of qualitative and semiquantitative methods of FDG-PET interpretation.(37) Reviewers selected 19 studies (442 cases, 535 controls) found in PubMed or the Cochrane Library. The selected studies had various reference standards. Ten used qualitative FDG uptake criteria to characterize inflammation, six used semiquantitative criteria, and three used both. Meta-analyses were not performed. Overall, qualitative methods were more specific, but less sensitive, than semiquantitative methods. Diagnostic performance varied by vessel and by thresholds (cutoffs) for positivity. Results are shown in Table 6.

Treglia et al (2011) published a systematic review of PET and PET/CT in patients with LVV.(38) Reviewers searched PUBMED and Scopus for publications on the role of FDG-PET in LVV. Reviewers identified 32 studies (n=604 vasculitis patients). Selected publications related to diagnosis, assessment of disease activity, extent of disease, response to therapy, and prediction of relapse or complications. Reviewers did not pool findings. They concluded that: (1) PET and PET/CT may be useful for initial diagnosis and assessment of severity of disease; (2) appeared to be superior to MRI in the diagnosis of LVV, but not in assessing disease activity under immunosuppressive treatment, in predicting relapse, or in evaluating vascular complications; and (3) the role of these imaging methods in monitoring treatment response is unclear. Reviewers also concluded that “given the heterogeneity between studies with regard to PET analysis and diagnostic criteria, a standardization of the technique is needed.” The studies cited in support of using PET for diagnosing LVV had small sample sizes.

Besson et al (2011) published a systematic review and meta-analysis of FDG-PET for patients with suspected GCA based on a search of PUBMED, EMBASE, and the Cochrane databases.(39) Studies were included if they evaluated the performance of FDG-PET for the diagnosis of GCA, had at least eight participants, used ACR criteria as the reference standard to confirm diagnosis of GCA, and included a control group. Fourteen studies were selected; the number of participants in those studies was unclear. Six studies with 283 participants (101 vasculitis, 182 controls) were included in a meta-analysis. The meta-analysis calculated pooled estimates of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratio, and diagnostic accuracy using a random-effects model. Results are shown in Table 6. There was statistically significant between-study heterogeneity for sensitivity, PPV, and NPV. All studies in the meta-analysis were small case-control studies.

**Table 6. Results of Systematic Reviews Assessing Use of FDG-PET for LVV**

Study	Studies	N	Outcomes	Estimate (95% CI)
Gonzalez-Garcia et al (2024)	17	1042	Prevalence of extracranial LVV as assessed by FDG-PET	<ul style="list-style-type: none"> <li>• Patients with GCA: 60.1% (44.2% to 74.9%)</li> <li>• Patients with polymyalgia rheumatica: 41.8% (26.7% to 57.8%)</li> </ul>
Lee et al (2016)	8	400	Diagnostic accuracy of PET and PET/CT for GCA and TA	<ul style="list-style-type: none"> <li>• Sensitivity: 76% (68% to 82%)</li> <li>• Specificity: 93% (89% to 96%)</li> <li>• PLR: 7.27 (3.71 to 14.24)</li> <li>• NLR: 0.30 (0.23 to 0.40)</li> </ul>
	3	133	Diagnostic accuracy of PET and PET/CT for GCA	<ul style="list-style-type: none"> <li>• Sensitivity: 83% (72% to 91%)</li> <li>• Specificity: 90% (80% to 96%)</li> <li>• PLR: 7.11 (2.91 to 17.4)</li> <li>• NLR: 0.20 (0.11 to 0.34)</li> </ul>

Soussan et al (2015)	4	233	Diagnostic accuracy for GCA	<ul style="list-style-type: none"> <li>• Sensitivity: 89.5% (78.5% to 96.0%)</li> <li>• Specificity: 97.7% (94% to 99%)</li> <li>• PLR: 28.7 (11.5 to 71.6)</li> <li>• NLR: 0.15 (0.07 to 0.29)</li> </ul>
	7	237	Diagnostic accuracy for disease activity in TA	<ul style="list-style-type: none"> <li>• Sensitivity: 87% (78% to 93%)</li> <li>• Specificity: 73% (63% to 81%)</li> <li>• PLR: 4.2 (1.5 to 12)</li> <li>• NLR: 0.2 (0.1 to 0.5)</li> </ul>
Puppo et al (2014)	10	633	Diagnostic accuracy for GCA	<ul style="list-style-type: none"> <li>• Sensitivity range: 56%-77%</li> <li>• Specificity range: 77%-100%</li> <li>• PPV range: 93%-100%</li> <li>• NPV range: 70%-82%</li> </ul>
	6	282	Diagnostic accuracy for GCA	<ul style="list-style-type: none"> <li>• Sensitivity range: 58%-90%</li> <li>• Specificity range: 42%-95%</li> <li>• PPV range: 79%-89%</li> <li>• NPV range: 95%-98%</li> </ul>
	3	72	Diagnostic accuracy for GCA	<ul style="list-style-type: none"> <li>• Sensitivity range: 65%-100%</li> <li>• Specificity range: 45%-100%</li> </ul>
Treglia et al (2011) <sup>42</sup>	32	604	Diagnostic accuracy for GCA and TA; assessment of disease activity; monitor treatment response	<ul style="list-style-type: none"> <li>• No pooling; concluded that FDG-PET is useful "in the initial diagnosis and in the assessment of activity and extent of disease in patients with LVV"</li> </ul>
Besson et al (2011) <sup>43</sup>	6	283	Diagnostic accuracy for GCA	<ul style="list-style-type: none"> <li>• Sensitivity: 80% (63% to 91%)</li> <li>• Specificity: 89% (78% to 94%)</li> <li>• PPV: 85% (62% to 95%)</li> <li>• NPV: 88% (72% to 95%)</li> <li>• PLR: 6.73 (3.55 to 12.77)</li> <li>• NLR: 0.25 (0.13 to 0.46)</li> </ul>

CI: confidence interval; CT: computed tomography; FDG: fluorine 18 fluorodeoxyglucose; GCA: giant cell arteritis; LVV: large vessel vasculitis; NLR: negative likelihood ratio; NPV: negative predictive value; PET: positron emission tomography; PLR: positive likelihood ratio; PPV: positive predictive value; TA: Takayasu arteritis.

## Observational Studies

Sammel et al (2019) evaluated the accuracy of FDG-PET/CT as a first-line test for GCA in the 'Giant Cell Arteritis and PET Scan' (GAPS) study.<sup>(41)</sup> The GAPS study prospectively enrolled 64 patients with newly suspected GCA from 13 sites in Sydney, Australia between May 2016 and July 2018. Blinded physicians rated the FDG-PET scans as globally positive or negative for GCA and their ratings were compared to temporal artery biopsy and clinical diagnosis at 6 months. Sensitivity was 92% (95% CI, 62% to 100%) compared with temporal artery biopsy and 71% (95% CI, 48% to 89%) compared to clinical diagnosis. Specificity was 85% (95% CI, 71% to 94%) compared to temporal artery biopsy and 91% (95% CI, 78% to 97%)- compared to clinical diagnosis. Interpretation of these findings is limited by the small sample size, as evidenced by the wide 95% confidence intervals.

## Diverse Noncardiac or Nononcologic Conditions

### Clinical Context and Test Purpose

The purpose of FDG-PET in individuals with diverse noncardiac or nononcologic conditions is to confirm a diagnosis or to inform the decision on selecting treatment regimens.

### Systematic Reviews

Numerous systematic reviews have described the use of PET in patients with carotid stenosis;<sup>(42)</sup> inflammatory diseases;<sup>(43-47)</sup> fever of unknown origin;<sup>(48-50)</sup> hyper insulinemic hypoglycemia;<sup>(51,52)</sup> spondylodiscitis;<sup>(53)</sup> spinal infections;<sup>(54)</sup> mycobacterium infection;<sup>(55)</sup>

Creutzfeldt-Jakob disease;(56) vascular prosthetic graft infection;(57-59) prosthetic infection after knee or hip arthroplasty;(60,61) inflammatory bowel disease;(62) atypical parkinsonism;(63) and, Huntington disease.(64) Many studies cited in these reviews were small, retrospective, and lacked standard definitions of PET interpretation and positivity; many did not directly compare 1 modality with another in the same patient group or correlate the PET results in individual patients to improved clinical outcomes.

## Supplemental Information

### PRACTICE GUIDELINES AND POSITION STATEMENTS

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### American Academy of Neurology

Evidence-based practice parameters from the American Academy of Neurology (AAN) are summarized in Table 7.

**Table 7. Practice Parameters on Diagnosis of Dementia**

Practice Parameter	Date	PET Recommendation
Diagnosis of dementia <sup>92</sup>	2004: reaffirmed	PET imaging not recommended for routine use in diagnostic evaluation of dementia (LOR: moderate clinical certainty)
Early detection of dementia <sup>92</sup>	2003: reaffirmed	Not addressed
Diagnosis of new-onset PD <sup>92,93</sup>	2006: reaffirmed 2013; retired 2016	Evidence insufficient to support or refute FDG-PET as a means of distinguishing PD from other parkinsonian syndromes
Evaluation of depression, psychosis, and dementia in PD <sup>90</sup> .	2006; retired 2018	Not addressed
Mild cognitive impairment <sup>89,91</sup>	2001; 2017; 2018	Not addressed

FDG: fluorine 18 fluorodeoxyglucose; LOR: level of recommendation; PD: Parkinson disease; PET: positron emission tomography.

#### American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) (2019) published evidence-based, consensus guidelines on the diagnosis and prevention of periprosthetic joint infections.(65) The AAOS recommendation regarding FDG- PET is that there is limited strength of evidence supporting the use of FDG PET/CT to aid in the diagnosis of periprosthetic joint infections. The strength of the recommendation was rated as "limited," which was described as "Evidence from two or more 'Low' quality studies with consistent findings or evidence from a single 'Moderate' quality study recommending for or against the intervention or diagnostic test or the evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention."

#### American College of Radiology

Evidence and consensus-based appropriateness criteria from the American College of Radiology are summarized in Table 8.

**Table 8. Appropriateness Criteria for Miscellaneous Indications of FDG-PET/CT**

<b>Appropriateness Criteria</b>	<b>Last Reviewed</b>	<b>FDG-PET/CT Criteria</b>
Suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot)	2022	<ul style="list-style-type: none"> <li>May be appropriate for suspected osteomyelitis; may be appropriate for suspected osteomyelitis or soft tissue infection with implanted extra-articular surgical hardware; may be appropriate for suspected septic arthritis with arthroplasty or other implanted intra-articular surgical hardware.</li> </ul>
Movement Disorders and Neurodegenerative Diseases	2019	May be appropriate as initial imaging for rapidly progressive dementia, suspected CJD; usually not appropriate for chorea, suspected HD; may be appropriate for initial imaging of parkinsonian syndromes; usually not appropriate for initial imaging of suspected neurodegeneration with brain iron accumulation; usually not appropriate for initial imaging of suspected motor neuron disease
Diagnosis of dementia	2001, reaffirmed 2004	PET imaging not recommended for routine use in diagnostic evaluation of dementia (LOR: moderate clinical certainty)
Early detection of dementia	2001, reaffirmed 2003, 2015	Not addressed
Diagnosis of new onset-PD	2006: reaffirmed 2013; retired 2016	Evidence insufficient to support or refute FDG-PET as a means of distinguishing PD from other parkinsonian syndromes
Evaluation of depression, psychosis, and dementia in PD	2006	Not addressed
Dementia and movement disorders	2016	May be appropriate in patients with possible or probable AD and to differentiate suspected FTD, LBD, CJD, or vascular dementia; usually not appropriate in patients with suspected HD, clinical features of PD or hemochromatosis, or motoneuron disease
Imaging after total knee arthroplasty	2023	Usually not appropriate for routine follow-up of asymptomatic patient, in work-up for suspected periprosthetic infection, for evaluation of prosthetic loosening, or suspected periprosthetic or hardware fracture
Seizures and epilepsy	2014	Usually appropriate for surgical planning in medically refractory epilepsy; may be appropriate for new-onset seizure unrelated to trauma in adults (age $\geq 18$ y) and for posttraumatic (subacute or chronic), new-onset seizure; otherwise, usually not appropriate for new-onset seizure
Crohn disease	2014	Usually not appropriate
Fever without source - child	2015	May be appropriate. This procedure should not be used as the initial study. Consider if extensive clinical and imaging work-up is negative.
Suspected osteomyelitis of the foot in patients with DM	2012; revised 2019	Usually not appropriate for initial imaging. May be appropriate for soft tissue swelling with or without ulcer, suspected osteomyelitis or early neuropathic arthropathy changes of the foot in patients with DM, suspected osteomyelitis of the foot in patients with DM with or without neuropathic arthropathy, and additional imaging following radiographs.
Noncerebral Vasculitis	2021	Usually appropriate for initial imaging of suspected LVV (FDG-PET/CT). Usually not appropriate for initial imaging of suspected medium vessel vasculitis.

AD: Alzheimer disease; CJD: Creutzfeldt-Jakob disease; CT: computed tomography; DM: diabetes mellitus; FDG: fluorine 18 fluorodeoxyglucose; FTD: frontotemporal dementia; HD: Huntington disease; LBD: Lewy body disease; LOR: level of recommendation; LVV: large vessel vasculitis; PD: Parkinson disease; PET: positron emission tomography.

## Infectious Diseases Society of America

The Infectious Diseases Society of America (IDSA) and the International Working Group on the Diabetic Foot (2023) published a guideline on the treatment of diabetes-related foot infections.(97) The guideline recommends magnetic resonance imaging (MRI) if the diagnosis of diabetes-related osteomyelitis needs to be confirmed, but PET is recommended as an alternative to MRI (conditional recommendation, low quality of evidence). The supporting text cites evidence regarding the high specificity of FDG-PET in this setting.

The Infection Diseases Society of America (IDSA) and the Pediatric Infectious Diseases Society (2021) published an evidence-based guidelines on acute hematogenous osteomyelitis in children.(73) Studies that validate the utility of FDG-PET for diagnosing pediatric osteomyelitis were listed as a future research need.

The IDSA (2015) published evidence-based, consensus guidelines on the diagnosis and treatment of native vertebral osteomyelitis in adults.(74) The guidelines stated that PET “is highly sensitive for detecting chronic osteomyelitis. A negative PET scan excludes the diagnosis of osteomyelitis, including native vertebral osteomyelitis, as the sensitivity of the test is expected to be very high in view of the high concentration of red marrow in the axial skeleton.”

The IDSA (2013) published evidence-based, consensus guidelines on the diagnosis and management of prosthetic joint infections.(75) The guidelines concluded that PET should not be routinely used to diagnoses prosthetic joint infection (Strength of recommendation: B [based on moderate evidence; Quality of evidence: III [expert opinion and descriptive studies]).

## U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

Not applicable.

## ONGOING AND UNPUBLISHED CLINICAL TRIALS

Currently, unpublished trials that might influence this review are listed in Table 9.

**Table 9. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
NCT06558357	Evaluation of the Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica and Comparison With Others Inflammatory Rheumatic Diseases	210	Dec 2024 not yet recruiting
NCT06019975	FDG-PET in the Diagnosis of Autoimmune Encephalitis	90	Apr 2024 recruiting; but not results posted
NCT00194298	FDG-PET Imaging in Complicated Diabetic Foot	240	Jan 2020 active but not recruiting
<b>Unpublished</b>			
NCT03022968	Tau Brain Imaging in Typical and Atypical Alzheimer's Disease	24	Nov 2019

NCT02084147	PET-MRI: Evaluation, Optimization and Clinical Implementation	72	Oct 2018 (completed)
-------------	---	----	----------------------

NCT: national clinical trial

## Regulatory Status

Following the U.S. Food and Drug Administration’s (FDA) approval of the Penn-PET in 1989, a number of PET scan platforms have been cleared by FDA through the 510(k) process. These systems are intended to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and organ function for the evaluation of diseases, and disorders such as, but not limited to, cardiovascular disease, neurologic disorders, and cancer. The images produced by the system can aid in radiotherapy treatment planning and interventional radiology procedures.

PET radiopharmaceuticals have been evaluated and approved as drugs by FDA for use as diagnostic imaging agents. These radiopharmaceuticals are approved for specific conditions. In December 2009, FDA issued guidance for Current Good Manufacturing Practice for PET drug manufacturers (1) and, in August 2011, issued similar Current Good Manufacturing Practice guidance for small businesses compounding radiopharmaceuticals.(16) An additional final guidance document, issued in December 2012, required all PET drug manufacturers and compounders to operate under an approved new drug application (NDA) or abbreviated NDA, or investigational new drug application, by December 12, 2015.(3)

In 1994, the FDG radiotracer was originally approved by the U.S. Food and Drug Administration (FDA) through the new drug application (NDA 20-306) process. The original indication was for “the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.” Added indications in 2000 were for “Assessment of glucose metabolism to assist in the evaluation of malignancy...” and “Assessment of patients with coronary artery disease and left ventricular dysfunction....”

Multiple manufacturers have approved NDAs for FDG.(4)

Three radioactive tracers (florbetapir fluorine 18, florbetaben fluorine 18, Flutemetamol fluorine 18) that bind to amyloid beta and can be detected in vivo with PET have been approved by the U.S. Food and Drug Administration (FDA) for amyloid beta imaging in individuals who are being evaluated for cognitive decline. Amyloid beta plaque PET imaging is proposed as an adjunct to the clinical diagnosis of AD and as a component of identifying patients for amyloid beta plaque-targeting therapy.

## Government Regulations

### National:

#### **FDG PET for Refractory Seizures (220.6.9) Implementation Date 4/18/05**

Medicare covers FDG-PET for pre-surgical evaluation for the purpose of localization of a focus of refractory seizure activity.

Limitations: Covered only for pre-surgical evaluation.

## **FDG-PET for Dementia and Neurodegenerative Diseases (CAG-00088N); (220.6.13)**

Implemented 10/30/09

“Medicare covers FDG-PET scans for either the differential diagnosis of fronto-temporal dementia (FTD) and Alzheimer’s disease (AD) under specific requirements; OR, its use in a Centers for Medicare & Medicaid Services (CMS)-approved practical clinical trial focused on the utility of FDG-PET in the diagnosis or treatment of dementing neurodegenerative diseases”.(83)

Specific requirements for each indication are clarified in the document.

### **Nationally Covered Indications**

#### **1. FDG-PET Requirements for Coverage in the Differential Diagnosis of AD and FTD:**

An FDG-PET scan is considered reasonable and necessary in patients with a recent diagnosis of dementia and documented cognitive decline of at least 6 months, who meet diagnostic criteria for both AD and FTD. These patients have been evaluated for specific alternate neurodegenerative diseases or other causative factors, but the cause of the clinical symptoms remains uncertain.

The following additional conditions must be met before an FDG-PET scan will be covered:

- a. The patient’s onset, clinical presentation, or course of cognitive impairment is such that FTD is suspected as an alternative neurodegenerative cause of the cognitive decline. Specifically, symptoms such as social disinhibition, awkwardness, difficulties with language, or loss of executive function are more prominent early in the course of FTD than the memory loss typical of AD;
- b. The patient has had a comprehensive clinical evaluation (as defined by the American Academy of Neurology (AAN)) encompassing a medical history from the patient and a well-acquainted informant (including assessment of activities of daily living), physical and mental status examination (including formal documentation of cognitive decline occurring over at least 6 months) aided by cognitive scales or neuropsychological testing, laboratory tests, and structural imaging such as magnetic resonance imaging (MRI) or computed tomography (CT);
- c. The evaluation of the patient has been conducted by a physician experienced in the diagnosis and assessment of dementia;
- d. The evaluation of the patient did not clearly determine a specific neurodegenerative disease or other cause for the clinical symptoms, and information available through FDG-PET is reasonably expected to help clarify the diagnosis between FTD and AD and help guide future treatment;
- e. The FDG-PET scan is performed in a facility that has all the accreditation necessary to operate nuclear medicine equipment. The reading of the scan should be done by an expert in nuclear medicine, radiology, neurology, or psychiatry, with experience interpreting such scans in the presence of dementia;
- f. A brain single photon emission computed tomography (SPECT) or FDG-PET scan has not been obtained for the same indication.
  - The indication can be considered to be different in patients who exhibit important changes in scope or severity of cognitive decline, and meet all other qualifying criteria listed above and below (including the judgment that the likely diagnosis remains uncertain). The results of a prior SPECT or FDG-PET scan must have been inconclusive or, in the case of SPECT, difficult to interpret due to immature or inadequate technology. In these instances, an FDG-PET scan may be covered after

one year has passed from the time the first SPECT or FDG-PET scan was performed.

- g. The referring and billing provider(s) have documented the appropriate evaluation of the Medicare beneficiary. Providers should establish the medical necessity of an FDG-PET scan by ensuring that the following information has been collected and is maintained in the beneficiary medical record:
- Date of onset of symptoms;
  - Diagnosis of clinical syndrome (normal aging; mild cognitive impairment or MCI; mild, moderate or severe dementia);
  - Mini mental status exam (MMSE) or similar test score;
  - Presumptive cause (possible, probable, uncertain AD);
  - Any neuropsychological testing performed;
  - Results of any structural imaging (MRI or CT) performed;
  - Relevant laboratory tests (B12, thyroid hormone); and,
  - Number and name of prescribed medications.

The billing provider must furnish a copy of the FDG-PET scan result for use by CMS and its contractors upon request. These verification requirements are consistent with federal requirements set forth in 42 Code of Federal Regulations section 410.32 generally for diagnostic x-ray tests, diagnostic laboratory tests, and other tests. In summary, section 410.32 requires the billing physician and the referring physician to maintain information in the medical record of each patient to demonstrate medical necessity [410.32(d) (2)] and submit the information demonstrating medical necessity to CMS and/or its agents upon request [410.32(d)(3)(I)] (OMB number 0938-0685).

2. FDG-PET Requirements for Coverage in the Context of a CMS-approved Practical Clinical Trial Utilizing a Specific Protocol to Demonstrate the Utility of FDG-PET in the Diagnosis, and Treatment of Neurodegenerative Dementing Diseases
- An FDG-PET scan is considered reasonable and necessary in patients with mild cognitive impairment or early dementia (in clinical circumstances other than those specified in subparagraph 1) only in the context of an approved clinical trial that contains patient safeguards and protections to ensure proper administration, use and evaluation of the FDG-PET scan.
  - The clinical trial must compare patients who do and do not receive an FDG-PET scan and have as its goal to monitor, evaluate, and improve clinical outcomes. In addition, it must meet the following basic criteria:
    - a. Written protocol on file;
    - b. Institutional Review Board review and approval;
    - c. Scientific review and approval by two or more qualified individuals who are not part of the research team; and,
    - d. Certification that investigators have not been disqualified.

### **FDG-PET for Infection and Inflammation (220.6.16) Implementation Date 4/10/23**

#### **RETIRED**

Effective January 1, 2021, the Centers for Medicare & Medicaid Services determined that no national coverage determination (NCD) is appropriate at this time for FDG PET for Inflammation and Infection. In the absence of an NCD, coverage determinations will be made by the Medicare Administrative Contractors under section 1862(a)(1)(A) of the Social Security Act.

#### **Local:**

There is no local coverage determination on this topic.

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

## Related Policies

- Positron Emission Tomography (PET) Scans for Cardiac Applications
  - Positron Emission Tomography (PET) for Oncologic Applications
- 

## References

1. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP). 2009;  
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070306.pdf>.
2. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP) Small Entity Compliance Guide. 2011;  
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM266640.pdf>.
3. Food and Drug Administration (FDA). Guidance: Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs. Silver Spring, MD: Center for Drug Evaluation and Research; December 2012;  
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291573.pdf>.
4. Food and Drug Administration (FDA). Positron Emission Tomography Drug Products; Safety and Effectiveness of Certain PET Drugs for Specific Indications. *Federal Register*. 2000; 65(48):12999-13010.
5. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) in the Management of Seizure Disorders. TEC Assessments. 1996; Volume 11: Tab 33.
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) for the Assessment of Cerebrovascular Disease. TEC Assessments. 1996; Volume 11:Tab 35.
7. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) of Central Nervous System Diseases. TEC Assessments. 1992; Volume 7: Tab 3.
8. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med*. Sep 8 2011;365(10):919-926.
9. Mishra AM, Bai H, Gribizis A, et al. Neuroimaging biomarkers of epileptogenesis. *Neurosci Lett*. Jun 27 2011;497(3):194-204.
10. Engel J, Cascino G, Ness P, et al. Outcome with respect to epileptic seizures. In: Engel J, ed. *Surgical Treatment of the Epilepsies*. New York, NY: Raven Press; 1993:609-621.

11. Niu N, Xing H, Wu M, et al. Performance of PET imaging for the localization of epileptogenic zone in patients with epilepsy: a meta-analysis. *Eur Radiol.* Aug 2021; 31(8): 6353-6366. PMID 33523306
12. Jones AL, Cascino GD. Evidence on use of neuroimaging for surgical treatment of temporal lobe epilepsy: a systematic review. *JAMA Neurol.* Apr 1 2016;73(4):464-470.
13. Wang X, Zhang C, Wang Y, et al. Prognostic factors for seizure outcome in patients with MRI-negative temporal lobe epilepsy: A meta-analysis and systematic review. *Seizure.* May 2016;38:54-62.
14. Burneo JG, Poon R, Kellett S, et al. The utility of positron emission tomography in epilepsy. *Can J Neurol Sci.* Nov 2015;42(6):360-371
15. Englot DJ, Wang DD, Rolston JD et al. Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. *J Neurosurg* 2012; 116(5):1042-8.
16. Willmann O, Wennberg R, May T et al. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy: a meta-analysis. *Seizure* 2007; 16(6):509-20.
17. Traub-Weidinger T, Weidinger P, Groppe G, et al. Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of 18F-FDG PET. *J Neurosurg Pediatr.* Dec 2016;25(6):683-688. PMID 27611898
18. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis.* Oct 1 2004;39(7):885-910.
19. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. *Clin Infect Dis.* Aug 15 2008;47(4):519-527.
20. Llewellyn A, Kraft J, Holton C, et al. Imaging for detection of osteomyelitis in people with diabetic foot ulcers: A systematic review and meta-analysis. *Eur J Radiol.* Oct 2020; 131:109215. PMID 32862106
21. Lauri C, Tamminga M, Glaudemans A, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. *Diabetes Care.* Aug 2017;40(8):1111-1120. PMID 28733376
22. Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. *Foot (Edinb).* Dec 2013;23(4):140-148. PMID 23906976
23. Termaat MF, Raijmakers PG, Scholten HJ et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. *J Bone Joint Surg Am* 2005; 87(11):2464-71.
24. de Winter F, van de Wiele C, Vogelaers D et al. Fluorine-18 fluorodeoxyglucose-positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic skeletal infections. *J Bone Joint Surg Am* 2001; 83-A(5):651-60.
25. Schiesser M, Stumpe KD, Trentz O et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. *Radiology* 2003; 226(2):391-8.
26. Guhlmann A, Brecht-Krauss D, Suger G et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. *J Nucl Med* 1998; 39(12):2145-52.
27. Meller J, Koster G, Liersch T et al. Chronic bacterial osteomyelitis: prospective comparison of (18)F-FDG imaging with a dual-head coincidence camera and (111)In-labelled autologous leucocyte scintigraphy. *Eur J Nucl Med Mol Imaging* 2002; 29(1):53-60.

28. Rastogi A, Bhattacharya A, Prakash M, et al. Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot's neuroarthropathy. *Nucl Med Commun*. Dec 2016;37(12):1253-1259. PMID 27749777
29. Gulati A, Bagga A. Large vessel vasculitis. *Pediatr Nephrol*. Jun 2010;25(6):1037-1048.
30. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum*. Aug 1990;33(8):1129-1134.
31. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum*. Aug 1990;33(8):1122-1128.
32. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. Jan 2013;65(1):1-11.
33. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis*. Mar 2009;68(3):318-323.
34. van der Geest KSM, Treglia G, Glaudemans AWJM, et al. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. May 03 2021. PMID 33942141
35. Lee YH, Choi SJ, Ji JD, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. *Z Rheumatol*. Nov 2016;75(9):924-931. PMID 26704559
36. Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. *Medicine (Baltimore)*. Apr 2015;94(14):e622. PMID 25860208
37. Puppo C, Massollo M, Paparo F, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. *Biomed Res Int*. 2014;2014:574248. PMID 25254211
38. Treglia G, Mattoli MV, Leccisotti L et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. *Clin Rheumatol* 2011; 30(10):1265-75.
39. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of (1)(8)F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. Sep 2011;38(9):1764-1772.
40. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med*. Jun 1 1994;120(11):919-929
41. Sammel AM, Hsiao E, Schembri G, et al. Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional Study. *Arthritis Rheumatol*. Aug 2019; 71(8): 1319-1328. PMID 30848549
42. Gupta A, Baradaran H, Schweitzer AD, et al. Oxygen extraction fraction and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. *AJNR Am J Neuroradiol*. Feb 2014;35(2):250-255.
43. Kim SJ, Pak K, Kim K, et al. Comparing the Diagnostic Accuracies of F-18 Fluorodeoxyglucose Positron Emission Tomography and Magnetic Resonance Imaging for the Detection of Spondylodiscitis: A Meta-analysis. *Spine (Phila Pa 1976)*. Apr 01 2019; 44(7): E414-E422. PMID 30889146
44. Yan J, Zhang C, Niu Y, et al. The role of 18F-FDG PET/CT in infectious endocarditis: a systematic review and meta-analysis. *Int J Clin Pharmacol Ther*. May 2016;54(5):337-342.
45. Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. *RMD Open*. 2015;1(1):e000100.

46. Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. *Sarcoidosis Vasc Diffuse Lung Dis.* Oct 2011; 28(2): 87-94. PMID 22117499
47. Yin Y, Liu X, Yang X, et al. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis. *Spine J.* Dec 2018; 18(12): 2323-2332. PMID 30121323
48. Hao R, Yuan L, Kan Y, et al. Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. *Nucl Med Commun.* Jul 2013;34(7):682-688.
49. Besson FL, Chaumet-Riffaud P, Playe M, et al. Contribution of 18F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. *Eur J Nucl Med Mol Imaging.* Sep 2016;43(10):1887-1895. PMID 27037917
50. Bharucha T, Rutherford A, Skeoch S, et al. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. *Clin Radiol.* Sep 2017;72(9):764-771. PMID 28600002
51. Kapoor RR, James C, Hussain K. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. *Nat Clin Pract Endocrinol Metab.* Feb 2009;5(2):101-112.
52. Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. *Nucl Med Commun.* Apr 2013;34(4):347-353.
53. Prodromou ML, Ziakas PD, Poulou LS, et al. FDG PET Is a Robust Tool for the Diagnosis of Spondylodiscitis: A Meta-analysis of Diagnostic Data. *Clin Nucl Med.* Jan 17 2014. PMID 24445277
54. Treglia G, Pascale M, Lazzeri E, et al. Diagnostic performance of 18 F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. *Eur J Nucl Med Mol Imaging.* May 2020; 47(5): 1287-1301. PMID 31729539
55. Treglia G, Taralli S, Calcagni ML et al. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. *J Comput Assist Tomogr* 2011; 35(3):387-93. PMID 21586936
56. Caobelli F, Cobelli M, Pizzocaro C, et al. The role of neuroimaging in evaluating patients affected by creutzfeldt-jakob disease: a systematic review of the literature. *J Neuroimaging.* Jan 2015;25(1):2-13.
57. Saleem BR, Pol RA, Slart RH, et al. 18F-Fluorodeoxyglucose positron emission tomography/CT scanning in diagnosing vascular prosthetic graft infection. *Biomed Res Int.* 2014;2014:471971.
58. Kim SJ, Lee SW, Jeong SY, et al. A systematic review and meta-analysis of 18 F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography for detection of infected prosthetic vascular grafts. *J Vasc Surg.* Jul 2019; 70(1): 307-313. PMID 30922755
59. Mahmoodi Z, Salarzaei M, Sheikh M. Prosthetic vascular graft infection: A systematic review and meta-analysis on diagnostic accuracy of 18FDG PET/CT. *Gen Thorac Cardiovasc Surg.* Jul 26 2021. PMID 34309812
60. Jin H, Yuan L, Li C, et al. Diagnostic performance of FDG PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis. *Q J Nucl Med Mol Imaging.* Mar 2014;58(1):85-93.
61. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* Nov 2008; 35(11): 2122-32. PMID 18704405

62. Zhang J, Li LF, Zhu YJ, et al. Diagnostic performance of 18F-FDG-PET versus scintigraphy in patients with inflammatory bowel disease: a meta-analysis of prospective literature. *Nucl Med Commun*. Dec 2014;35(12):1233-1246.
63. Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. *Eur J Nucl Med Mol Imaging*. Nov 2016;43(12):2244-2254. PMID 27470326
64. Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. *Eur J Nucl Med Mol Imaging*. Jun 2016;43(6):1171-1182.
65. American Academy of Orthopaedic Surgeons (AAOS). The diagnosis and prevention of periprosthetic joint infections: evidence-based clinical practice guidelines.2019; <https://www.aaos.org/globalassets/quality-and-practice-resources/pji/pji-clinical-practice-guideline-final-9-18-19-.pdf>.
66. Beaman FD, von Herrmann PF, Kransdorf MJ, et al. ACR Appropriateness Criteria (R) Suspected Osteomyelitis, Septic Arthritis, or Soft Tissue Infection (Excluding Spine and Diabetic Foot). *J Am Coll Radiol*. May 2017; 14(5S): S326-S337. PMID 28473089
67. American College of Radiology. ACR appropriateness criteria: imaging after total knee arthroplasty. 2017; retrieved August 20, 2019 from: <https://acsearch.acr.org/docs/69430/Narrative/>.
68. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. *Clin Nucl Med*. Feb 2016; 41(2): 118-25. PMID 26646994
69. American College of Radiology. ACR appropriateness criteria: seizures and epilepsy. 2019; <https://acsearch.acr.org/docs/69479/Narrative/>.
70. American College of Radiology. ACR appropriateness criteria: Crohn disease. 2019; <https://acsearch.acr.org/docs/69470/Narrative/>.
71. American College of Radiology. ACR appropriateness criteria: suspected osteomyelitis of the foot in patients with diabetes mellitus. 2019; <https://acsearch.acr.org/docs/69340/Narrative/>.
72. American College of Radiology. ACR appropriateness criteria: Noncerebral Vasculitis. 2021; <https://acsearch.acr.org/docs/3158180/Narrative/>.
73. Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. *J Pediatric Infect Dis Soc*. Aug 05 2021. PMID 34350458
74. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis*. Sep 15 2015;61(6):e26-46. PMID 26229122
75. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. Jan 2013;56(1):e1-e25. PMID 23223583
76. Courtney MR, Antonic-Baker A, Chen Z, et al. Association of Localizing 18 F-FDG-PET Hypometabolism and Outcome Following Epilepsy Surgery: Systematic Review and Meta-Analysis. *Neurology*. May 14 2024; 102(9): e209304. PMID 38626375
77. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for FDG PET for Infection and Inflammation (220.6.16). 2023 RETIRED; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=323&ncdver=2&keyword=fdg&keywordType=starts&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>.
78. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG-

- 00088R). 2004; [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+\(FDG\)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+\(1st+Recon\)&bc=AiAAAAAAEAAA&](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+(FDG)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+(1st+Recon)&bc=AiAAAAAAEAAA&).
79. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for FDG PET for Dementia and Neurodegenerative Diseases (220.6.13). 2009; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=288&ncdver=3&DocID=220.6.13&SearchType=Advanced&bc=IAAABAAAAAAA%3d%3d&>.
  80. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for FDG PET for Refractory Seizures (220.6.9). 2005; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=294&ncdver=1&keyword=fdg&keywordType=starts&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>.
  81. Smailagic N, Vacante M, Hyde C, et al. (1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2015;1:CD010632. PMID 25629415
  82. Davison CM, O'Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. *Int J Geriatr Psychiatry*. Jun 2014;29(6):551-561. PMID 24123413
  83. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. *J Alzheimers Dis*. 2011;26(4):627-645.
  84. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose—positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. *AJNR Am J Neuroradiol*. 2009;30(2):404-410.
  85. Matchar DB, Kulasingam SL, McCrory DC, et al. *Use of Positron Emission Tomography and Other Neuroimaging Techniques in the Diagnosis and Management of Alzheimer's Disease and Dementia*. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
  86. Zhu L, Zhao W, Chen J, et al. Systematic review and meta-analysis of diagnostic test accuracy (DTA) studies: the role of cerebral perfusion imaging in prognosis evaluation of mild cognitive impairment. *Ann Palliat Med*. Feb 2022; 11(2): 673-683. PMID 35249345
  87. Jin Y, Huang K, Shao T. [ 18 F]Fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography and conventional imaging modalities in the diagnosis of diabetic foot osteomyelitis: a meta-analysis. *Clin Radiol*. Sep 2024; 79(9): e1142-e1151. PMID 38880677
  88. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. May 8, 2001;56(9):1143-1153.
  89. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. May 8 2001;56(9):1133-1142.
  90. Aarsland D, Emre M, Lees A, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Jan 2 2007;68(1):80; author reply 81.

91. American Academy of Neurology. Guideline Summary: Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2018; retrieved July 30, 2019 from: <https://www.guidelinecentral.com/summaries/practice-guideline-update-summary-mild-cognitive-impairment-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology/#section-405>.
92. Wippold FJ, 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria dementia and movement disorders. J Am Coll Radiol. 2015;12(1):19-28.
93. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. Clin Nucl Med. Feb 2016;41(2):118-125. PMID 26646994
94. Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19(12):e131-40, 1487-501. PMID: 22900895
95. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120-6.
96. González-García A, Fabregate M, Serralta G, et al. The utility of 18 F-FDG-PET/CT in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis. A systematic review and meta-analysis. Rev Clin Esp (Barc). 2024; 224(7): 445-456. PMID 38852739
97. Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. Oct 02 2023. PMID 37779457

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through September 10, 2025, the date the research was completed.*

**Joint BCBSM/BCN Medical Policy History**

<b>Policy Effective Date</b>	<b>BCBSM Signature Date</b>	<b>BCN Signature Date</b>	<b>Comments</b>
11/13/02	11/13/02	11/13/02	Joint policy established
3/1/07	12/28/06	9/18/09	Routine maintenance; new diagnoses added
11/1/08	8/19/08	10/30/08	Maintenance, combined PET for brain-non-oncologic and initial diagnosis of breast cancer with this policy; added PET for myocardial indications
5/1/09	2/10/09	2/10/09	Maintenance, initial diagnosis of breast cancer added as investigational to PET scan policy
9/1/09	6/16/09	6/16/09	Redefined criteria for PET myocardial perfusion
7/1/11	4/19/11	5/3/11	Additional references added. Clarified indications for PET for oncologic conditions.
1/1/12	10/11/11	11/9/11	Joint policy established; separated "PET Scans for Miscellaneous Conditions" policy from combined joint policy "PET Scans" to mirror BCBSA policy. See prior history below.
5/1/14	2/18/14	3/3/14	Routine maintenance: <ul style="list-style-type: none"> <li>• Removed procedure codes A9526, A9552, and A9580.</li> <li>• Added inflammatory bowel disease as experimental/investigational indications.</li> <li>• Added "Non-cardiac, non-oncologic" to policy title.</li> <li>• Updated description, rationale and references.</li> <li>• Clarified description of type of seizures qualifying for PET scan as a diagnostic tool.</li> </ul>

9/1/15	6/16/15	7/16/15	<p>Routine maintenance</p> <ul style="list-style-type: none"> <li>Updated criteria: Vascular prosthetic graft infection, sarcoidosis, fever of unknown origin, and inflammation of unknown origin added as investigational indications. Acanthocytosis and assessment of cerebral blood flow in newborns revise, but no change to intent.</li> <li>References and rationale updated.</li> </ul>
9/1/16	6/21/16	6/21/16	Routine maintenance
9/1/17	6/20/17	6/20/17	<p>Routine maintenance</p> <p>Added “Fluorodeoxyglucose F 18” to policy title</p> <p>Added procedure code A9552</p>
9/1/18	6/19/18	6/19/18	<ul style="list-style-type: none"> <li>Routine maintenance</li> <li>Codes added – 78814, 78815, 78816</li> <li>Title simplified to maintain coordination with other PET scan policies</li> </ul>
7/1/19	4/16/19		<ul style="list-style-type: none"> <li>Routine maintenance</li> </ul>
7/1/20	4/14/20		<ul style="list-style-type: none"> <li>Routine maintenance</li> </ul>
7/1/21	4/20/21		<ul style="list-style-type: none"> <li>Routine maintenance</li> </ul>
7/1/22	4/19/22		<ul style="list-style-type: none"> <li>Routine maintenance</li> <li>Cover PET for differentiation of FTD vs Alzheimer’s disease</li> </ul>
7/1/23	4/18/23		<ul style="list-style-type: none"> <li>Routine maintenance</li> <li>Added codes: A9601 eff 7/1/22 and A9602 eff 10/1/22 as E/I per code update.</li> <li>BCBSA updated policy 6.01.06 - Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography on 10/13/22.</li> <li>BCBSA transferred Alzheimer and dementia information and criteria to PET for eval of</li> </ul>

			<p>Alzheimer disease on 9/9/21 to policy 6.01.55 - Selected Positron Emission Tomography Technologies for Evaluation of Alzheimer Disease, last updated on 10/13/22. Determination made at 4/19/21 JUMP to keep dementia and Alzheimer's information in this policy</p> <ul style="list-style-type: none"> <li>○ This JUMP policy discusses only PET with fluorine 18 fluorodeoxyglucose whereas the BCBSA Alzheimer policy addresses beta-amyloid as well (all EI)</li> <li>● Vendor: Carelon. Covers: <ul style="list-style-type: none"> <li>○ PET when used to distinguish between frontotemporal dementia (FTD) and Alzheimer's <ul style="list-style-type: none"> <li>▪ Inclusion added <ul style="list-style-type: none"> <li>● In line with Medicare</li> <li>● Diverges with BCBSA – EI (ky)</li> </ul> </li> </ul> </li> </ul> </li> </ul>
7/1/24	4/16/24		<ul style="list-style-type: none"> <li>● Routine maintenance</li> <li>● Vendor: Carelon (ky)</li> </ul>
7/1/25	4/15/25		<ul style="list-style-type: none"> <li>● Routine maintenance</li> <li>● Vendor: Carelon (ky)</li> </ul>
1/1/26	10/21/25		<ul style="list-style-type: none"> <li>● Off cycle review (slp)</li> <li>● Code added A9586 as EST</li> <li>● Formatting updated</li> <li>● Q9982 and Q9983 moved from EI to EST and criteria added for FDA approved tracers</li> <li>● Exclusions clarified – testing is not approved to confirm “suspected” Alzheimer's.</li> </ul>

Next Review Date: 2nd Qtr, 2026

Pre-Consolidation Medical Policy History

Original Policy Date	Comments
BCN: 10/12/98	Revised: 5/8/01, 1/4/02
BCBSM: 10/30/00	Revised: 12/4/00

**BLUE CARE NETWORK BENEFIT COVERAGE**  
**POLICY: POSITRON EMISSION TOMOGRAPHY (PET) FOR MISCELLANEOUS**  
**APPLICATIONS (NON-CARDIAC, NON-ONCOLOGIC)**

**I. Coverage Determination:**

<b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b>	Covered; criteria apply
<b>BCNA (Medicare Advantage)</b>	Refer to Medicare information under the Government Regulations section of this policy.
<b>BCN65 (Medicare Complementary)</b>	Coinsurance covered if primary Medicare covers the service.

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.